The Dareon®-5 Trial - epNEC expansion cohort1
This is an expansion cohort (Part 2) of the Dareon® - 5 trial to be conducted at the selected target dose in adult patients with locally advanced or metastatic extrapulmonary neuroendocrine carcinoma (epNEC) whose tumours have DLL3 high expression and whose disease has progressed during or following platinum-based chemotherapy.
The Dareon®–5 trial is now actively enrolling epNEC patients with DLL3 high expression.
Patients may be eligible to participate if they:
Are 18 years of age or older.
Have histologically or cytologically confirmed epNEC (except Merkel cell carcinoma, Medullary thyroid cancer and Neuroendocrine prostate cancer) with centrally assessed DLL3 high expression status.
Have relapsed/refractory extra-pulmonary NECs, after ≥1 prior line of therapy.
Have at least one measurable lesion within 21 days prior to the first dose of obrixtamig.
Meet additional trial criteria
Share with a Colleague
Your help in creating awareness of this trial is appreciated. Click below to share this site with colleagues in your medical community:
Study information available in clinicaltrials.gov: NCT05882058
Pipeline compound(s) are under pre-clinical and/or clinical investigation and have not been approved by regulatory authorities for commercial use in patients. Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.